TG Therapeutics Investigational Trial Site

Milwaukee, Wisconsin 53226

3 studies enrolling now · 6 studies all time

What they study most

B-cell Mediated Autoimmune Disorders, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Multiple Sclerosis, Non Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma, Relapsing Multiple Sclerosis

Studies at this site

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — Recruiting now
• A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders — Recruiting now
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — Recruiting now
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia — Stopped early
• Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials — Stopped early
• Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies — Completed